ArticleBMC microbiology2025
Genomic insights into tigecycline non-susceptibility in Clostridioides difficile: the role of the Tet P determinant and efflux mechanisms.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Isolation of Clostridioides difficile from the atmospheric fine particulate matter.BMC microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundClostridioides difficile infection (CDI) is a significant cause of nosocomial infections, often arising from antibiotic-induced disruption of the normal gut microbiota, enabling C. difficile proliferation. Tigecycline has proven effective in treating refractory CDI, with resistance to this antibiotic being rare. However, our previous study identified six C. difficile isolates that were non-susceptible to tigecyclin.
methodsTo investigate the mechanisms underlying reduced tigecycline susceptibility, the genome of C. difficile strain 16338, which is non-susceptible to tigecycline, was characterized. The tetA(P), tetB(P), and Tet P (including 2,000 bp upstream), were individually cloned into recombinant plasmids and transferred into Escherichia coli to assess their contribution to tigecycline resistance. The role of promoter and terminator sequences was explored by comparing the minimum inhibitory concentrations (MICs) of strains with different combinations. Efflux pump involvement in resistance was evaluated using efflux pump inhibitors.
resultsWhole-genome sequencing revealed that C. difficile 16338 lacked plasmids and contained the Tet P determinant on its chromosome. The Tet P determinant contains two coding genes, tetA(P) and tetB(P), and is associated with an insertion sequence containing an 11-bp repeat sequence, which may serve as a recombination site facilitating gene transfer. E. coli strains carrying tetP, tetA(P), or tetB(P) exhibited a 1-fold increase in MIC for tigecycline. Additionally, tetA(P) and tetB(P) primarily mediate resistance to tetracycline (MIC = 32 mg/L) and minocycline (MIC = 32 mg/L), respectively. In addition, strains carrying different P3 promoters and T1 terminator sequences exhibited varying MICs for tigecycline. Efflux pumps were implicated in tigecycline resistance, as inhibitors (CCCP and reserpine) reduced MIC by one-fold.
conclusionThis study identified the Tet P determinant and its related encoding genes tetA(P) and tetB(P) as genetic factors associated with reduced susceptibility to tigecycline in C. difficile. The tetA(P) and tetB(P) genes mediate different resistance to tetracycline and minocycline, showing substrate specificity. Although the efflux mechanism is associated with reduced susceptibility to tigecycline, further studies are needed to determine whether it is only the efflux pump encoded by tetA(P) that is responsible. These findings enhance our understanding of tigecycline resistance in C. difficile and lay the foundation for future studies of potential resistance mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.